Insider

GE HealthCare reports $1.36 diluted EPS and plans to acquire SOFIE Biosciences

On October 28, 2026, GE HealthCare reported third-quarter financial results, posting diluted earnings per share (EPS) of $1.36 and quarterly revenue of $5,513 million. Simultaneously, the company announced plans to acquire SOFIE Biosciences for $945 million in cash and leadership changes at the Patient Care Solutions division.

Verified against 6 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
A white medical radiation therapy machine with a black patient table in a clinic
Photo by Accuray on Unsplash
$5,513 million
Quarterly revenue
$615 million
Net income
$945 million
Planned acquisition cost

Quarterly financial results

In the third quarter of 2026, the company generated $5,513 million in revenue, up 7.2% from the same period last year. Net income attributable to GE HealthCare was $615 million, an increase of 37.9%. Meanwhile, direct tariffs negatively impacted operating income by $53 million for the quarter, although the company received $55 million in tariff refunds.

Quarter vs the same quarter a year earlier

Jul–Sep 2025Jul–Sep 2026Revenue+7.2%$5.1B$5.5BNet income+37.9%$446M$615M
Data from the original sources listed alongside.

Revenue by quarter, $B

5.3Q4 '24*15.1%4.8Q1 '2513.2%5Q2 '2513.1%5.1Q3 '2512.7%5.7Q4 '25*14.5%5.1Q1 '2610%5.3Q2 '2614%5.5Q3 '2614.6%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Leadership changes and strategic plans

The company announced a planned acquisition of SOFIE Biosciences for $945 million in cash. Additionally, there will be a leadership change at the Patient Care Solutions division: Jeannette Bankes will leave her role as president and CEO of the division on November 15, 2026, and Neal Sandy will replace her on November 16, 2026.

Previously, on September 22, 2026, the company announced the appointment of Pascal Desroches to the board of directors, effective January 4, 2027.

Original sources

  1. 8-K filing, October 28, 2026October 28, 2026SHA-256 of our archived copy 11ebdc2b7300…
  2. 8-K EX-99 filing, October 28, 2026October 28, 2026SHA-256 of our archived copy eb416d2e0cb5…
  3. financial data (XBRL)October 28, 2026SHA-256 of our archived copy 21c170857621…
  4. 10-Q filing, October 28, 2026October 28, 2026SHA-256 of our archived copy c38d344c0c64…
  5. 8-K EX-99 filing, September 22, 2026September 22, 2026SHA-256 of our archived copy 7bc61efee38e…
  6. 8-K filing, September 22, 2026September 22, 2026SHA-256 of our archived copy 1c20a405e164…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards